Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is -10.02% lower on its value in year-to-date trading and has touched a low of $4.71 and a high of $10.67 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AUPH stock was last observed hovering at around $7.98 in the last trading session, with the day’s gains setting it 0.1%.
Currently trading at $8.08, the stock is 1.80% and -1.37% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.6 million and changing 1.25% at the moment leaves the stock 14.08% off its SMA200. AUPH registered 41.26% gain for a year compared to 6-month gain of 17.10%.
The stock witnessed a 1.64% loss in the last 1 month and extending the period to 3 months gives it a -8.70%, and is 0.62% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.42% over the week and 4.42% over the month.
Aurinia Pharmaceuticals Inc (AUPH) has around 130 employees, a market worth around $1.11B and $235.13M in sales. Current P/E ratio is 209.33 and Fwd P/E is 10.77. Profit margin for the company is 2.45%. Distance from 52-week low is 71.55% and -24.27% from its 52-week high. The company has generated returns on investments over the last 12 months (1.30%).
with sales reaching $61.06M over the same period.The EPS is expected to grow by 1015.00% this year, but quarterly earnings will post 9.97% year-over-year. Quarterly sales are estimated to grow 21.38% in year-over-year returns.
Aurinia Pharmaceuticals Inc (AUPH) Top Institutional Holders
The shares outstanding are 140.88M, and float is at 123.53M with Short Float at 8.07%.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 11.14 million shares valued at $63.59 million. The investor’s holdings represent 7.7696% of the AUPH Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.27 million shares valued at $$52.94 million to account for 6.4384 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 3.97 million shares representing 2.7698% and valued at over $22.67 million, while STATE STREET CORP holds 2.0095 of the shares totaling 2.88 million with a market value of $16.45 million.
Aurinia Pharmaceuticals Inc (AUPH) Insider Activity
A total of 0 insider transactions have happened at Aurinia Pharmaceuticals Inc (AUPH) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Greenleaf Peter,the company’sChief Executive Officer. SEC filings show that Greenleaf Peter sold 195,593 shares of the company’s common stock on Mar 03 ’25 at a price of $8.00 per share for a total of $1.56 million. Following the sale, the insider now owns 1.95 million shares.
Aurinia Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 04 ’25 that Greenleaf Peter (Chief Executive Officer) sold a total of 164,947 shares of the company’s common stock. The trade occurred on Mar 04 ’25 and was made at $7.92 per share for $1.31 million. Following the transaction, the insider now directly holds 1.79 million shares of the AUPH stock.
Still, SEC filings show that on Mar 03 ’25, Keenan Greg (Chief Medical Officer) disposed off 12,239 shares at an average price of $8.00 for $97912.0. The insider now directly holds 161,789 shares of Aurinia Pharmaceuticals Inc (AUPH).
Aurinia Pharmaceuticals Inc (AUPH): Who are the competitors?
The company’s main competitors (and peers) include Regeneron Pharmaceuticals Inc. (REGN) that is trading -30.51% down over the past 12 months. COSCIENS Biopharma Inc. (CSCI) that is -64.29% lower over the same period.
